Program
tasimelteon
Also written as “Tasimelteon”, “Tasimelteon Oral Suspension” and “Tasimelteon Oral Capsule”.
Its studies are mostly in Sleep Disorders, Circadian Rhythm · Sleep Initiation and Maintenance Disorders · Depressive Disorder, Major · Renal Insufficiency · Liver Diseases, led by Vanda Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticals | 253 open or running | phase 4since May 1, 2014 | Feb 3, 2006 | Nov 2027phase 3 · NCT06953869 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Feb 3, 2006.
- Jan 26, 2012Phase 1 study in Renal InsufficiencyNCT01526746 · 32 enrolled · United States
- Feb 22, 2012Phase 1 study in Healthy VolunteersNCT01540500 · 24 enrolled · United States
- Apr 12, 2012Phase 1 study in Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With EthanolNCT01578057 · 28 enrolled · Canada
- Jun 28, 2012Phase 1 study in HealthyNCT01637636 · 48 enrolled · United States
- May 1, 2014Phase 4 study in Sleep Disorders, Circadian RhythmNCT02130999 · 14 enrolled
- Aug 29, 2014Phase 3 study in Smith-Magenis SyndromeNCT02231008 · 49 enrolled · United States
- May 16, 2016Phase 1 study in Sleep Disorders, Circadian RhythmNCT02776215 · 24 enrolled · United States
- Sep 8, 2016Phase 2 study in Jet Lag DisorderNCT03291041 · 25 enrolled · United States
- Oct 31, 2017Phase 3 study in Jet Lag Type InsomniaNCT03373201 · 320 enrolled · United States
- Oct 18, 2019Phase 1 study in Healthy VolunteersNCT06323655 · 48 enrolled · Canada
- Nov 19, 2020Phase 3 study in Sleep Wake DisordersNCT04652882 · 43 enrolled · United States, Austria, Germany
- Jul 5, 2022Phase 1 study in HealthyNCT05572281 · 36 enrolled · United States
- Nov 14, 2024Phase 3 study in Sleep Wake DisordersNCT06701396 · 60 planned · Turkey
- Apr 1, 2025Phase 3 study in Sleep Initiation and Maintenance DisordersNCT06953869 · 420 planned · United States, Germany, Poland and more
Ahead
- Nov 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT06953869
TargetBeta
“Melatonin receptor agonist”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06953869Sleep Initiation and Maintenance Disorders · United States, Germany, Poland and more | 3 | Recruiting | Nov 2027 | 420 |
| NCT06701396Sleep Wake Disorders · Turkey | 3 | Recruiting | Jun 30, 2025 | 60 |
| NCT05572281Healthy · United States | 1 | Completed | Jun 15, 2022 | 36 |
| NCT04652882Sleep Wake Disorders · United States, Austria, Germany | 3 | Completed | Sep 4, 2026 | 43 |
| NCT06323655Healthy Volunteers · Canada | 1 | Completed | Aug 28, 2018 | 48 |
| NCT03373201Jet Lag Type Insomnia · United States | 3 | Completed | Mar 5, 2018 | 320 |
| NCT03291041Jet Lag Disorder · United States | 2 | Completed | Nov 2017 | 25 |
| NCT02776215Sleep Disorders, Circadian Rhythm · United States | 1 | Completed | Dec 20, 2017 | 24 |
| NCT02231008Smith-Magenis Syndrome · United States | 3 | Completed | Nov 19, 2018 | 49 |
| NCT02130999Sleep Disorders, Circadian Rhythm | 4 | Completed | May 2014 | 14 |
| NCT01637636Healthy · United States | 1 | Completed | Aug 2012 | 48 |
| NCT01578057Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol · Canada | 1 | Completed | Jun 2012 | 28 |
| NCT01540500Healthy Volunteers · United States | 1 | Completed | Mar 2012 | 24 |
| NCT01526746Renal Insufficiency · United States | 1 | Completed | Jun 2012 | 32 |
| NCT01477619Healthy Volunteers · United States | 1 | Completed | Jan 2012 | 60 |
| NCT01428661Depressive Disorder, Major · United States | 3 | Completed | Jan 2013 | 507 |
| NCT01430754Sleep Disorders, Circadian Rhythm · United States | 3 | Completed | Dec 2012 | 20 |
| NCT01429116Sleep Disorders, Circadian Rhythm · United States | 3 | Completed | Jan 2015 | 200 |
| NCT01402076Healthy Volunteers · United States | 1 | Completed | Aug 2011 | 24 |
| NCT01271387Liver Diseases · United States | 1 | Completed | Aug 2011 | 29 |
| NCT01218789Sleep Disorders, Circadian Rhythm · France | 3 | Active, not recruiting | Dec 5, 2024 | 140 |
| NCT01163032Sleep Disorders, Circadian Rhythm · United States, Germany | 3 | Completed | Nov 2012 | 136 |
| NCT00548340Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Feb 2008 | 322 |
| NCT00490945Sleep Disorders, Circadian Rhythm · United States | 2 | Completed | Mar 2005 | 45 |
| NCT00291187Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Aug 2006 | 411 |
How it is read
Names in the registry
- “tasimelteon”, 11 entries
- “Tasimelteon”, 10 entries
- “Tasimelteon Oral Suspension”, 2 entries
- “Tasimelteon Oral Capsule”, 1 entry
- “tasimelteon 20 mg capsule”, 1 entry
Conditions, from the studies’ own filings
- Sleep Disorders, Circadian Rhythm, 9 studies
- Sleep Initiation and Maintenance Disorders, 4 studies
- Depressive Disorder, Major, 1 study
- Renal Insufficiency, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.